Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
Go back to Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026| (NASDAQ: ACON) | Delayed: 1.94 -0.01 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.95 | 52 Week High | $ | |||
| Open | $1.94 | 52 Week Low | $ | |||
| Day High | $1.99 | P/E | N/A | |||
| Day Low | $1.90 | EPS | $ | |||
| Volume | 15,046 | |||||
| (NASDAQ: ACONW) | Delayed: 0.03 +0.01 (50.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.02 | 52 Week High | $ | |||
| Open | $0.03 | 52 Week Low | $ | |||
| Day High | $0.03 | P/E | N/A | |||
| Day Low | $0.02 | EPS | $ | |||
| Volume | 103,390 | |||||



